Dr Penelope Ward appointed Glenmark's clinical R&D head
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals has appointed Dr Penelope Ward as president, clinical R&D, and chief medical officer. Dr Ward, who will be based at Glenmark’s clinical R&D centre in Oxford, UK, will oversee the entire clinical development activity for both new chemical and biological entities. She will also guide all medical activities across Glenmark's branded generic markets. Dr Ward, who has in the past held senior positions in companies such as Pharmacia and Upjohn, GlaxoSmithKline and Roche, was most recently chief medical officer at the Swiss biotechnology company, Novimmune.